ABSTRACT
INTRODUCTION
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of poorly differentiated non-small-cell lung carcinoma (NSCLC) that accounts for 0.1%-0.4% of all lung cancers [1] [2] [3] . PSC carries a poor prognosis compared to the other types of NSCLC even in early stage disease [4] . PSC typically occurs in older, heavy smoking men and has a predilection for upper lobe involvement [5, 6] . The sensitivity PSC to chemotherapy is controversial; however, surgery in early stage disease has demonstrated survival benefit [5, 7] .
Pathologically PSC demonstrates both epithelial and mesenchymal elements in the tumor distinguishing it from other types of NSCLC. PSC was initially described Virchow in 1865 as a "biphasic" lesion of adenocarcinomatous or squamous cell components along with spindle or giant cell elements forming at least 10% of the tumor mass [8] . This description fulfills the current WHO criteria for the diagnosis of PSC. Based on the WHO criteria, five subgroups of PSC exist: pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma [3] . Overall, it has proven difficult to formulate treatment recommendations for PSC due to its rarity, rapid progression and short survival, and heterogeneous pathological qualities.
Genomic analysis has revealed a common origin of both the epithelial and mesenchymal elements and it is thought that epithelial-mesenchymal transition (EMT) is the mechanism that gives rise to this tumor, with the epithelial elements, adenocarcinoma or squamous components, having undergone a transition to a poorlydifferentiated mesenchymal or "sarcomatoid" phenotype Research Paper www.impactjournals.com/oncotarget with the expression of mesenchymal proteins such as vimentin [9, 10] . Ultimately, efforts to study PSC have been hindered by the rarity of this NSCLC variant.
RESULTS
We identified 25 patients with a diagnosis of PSC (Table 1 ). The 16 men and 9 women had a median age of 57 years (range, 31-83 years). Chemotherapy was most often used in advanced stage disease (stage 3, 4). Unfortunately, treatment with systemic chemotherapy did not show a significant improvement in outcome (p = 0.451, HR 0.638). Patients who underwent surgery and systemic chemotherapy showed a trend toward improvement in outcome (p = 0.08 and HR 0.04). Their median OS was 457.6 days (95% CI 206-1187 days). Patients who underwent surgical resection only had the best median overall survival of 713.5 days (95% CI, 246-1138 days) ( Table 2 ).
All patients treated with systemic chemotherapy had a median OS of 375 days (95% CI, 114-600 days). In patients treated with systemic chemotherapy only, their median OS was 256 days (95% CI 114-600 days). These were patients with advanced disease at diagnosis. Patients who received neither chemotherapy nor surgery had a median OS of 205.5 (95% CI 98-447 days), (Figure 1 
DISCUSSION
The rarity pulmonary sarcomatoid carcinoma and the difficulty of pathological diagnosis make it a difficult malignancy to study. A search of PubMed entries between 01/01/1995 and 09/01/2016 using the keywords "pulmonary", "sarcomatoid", and "carcinoma" identified 11 retrospective studies addressing chemotherapy and surgical resection of PSC. Two studies have reported the median overall survival of PSC treated with systemic chemotherapy compared to no chemotherapy. Although limited in size, our study quantifies the median overall survival of patients with PSC treated with systemic chemotherapy and surgery, surgery alone, systemic chemotherapy alone, and no treatment. No study to date has compared the outcomes of these different patient groups in a single study. Table 3 shows our findings compared to other reports.
Prognosis of PSC is poor, even when compared to other types of NSCLC. The efficacy of systemic chemotherapy has varied with some studies showing no overall survival benefit and others showing a modest benefit [2, 5, 6, 11] . Our study demonstrates advanced PSC has minimal sensitivity to chemotherapy, with an increase median OS of 256 days with systemic chemotherapy only compared to 205.5 days without any treatment. Chemotherapy does not appear to significantly improve overall survival and may not be useful in advanced disease.
Surgery in early stage operable PSC has proven to be the greatest overall survival benefit and remains the standard of care among candidates. The results from our study are consistent with other reports and demonstrate an overall survival at 713.5 days with surgical intervention. Additionally, in patients who required chemotherapy, the patients who underwent systemic chemotherapy and surgery had an OS of 457.5 days compared to 256 days with chemotherapy alone.
In non-small cell lung carcinoma, alternatives to chemotherapy are under investigation with the development of molecular targeted therapies. Unfortunately, little data is available regarding targeted therapy in PSC. Studies have shown that the prevalence of epidermal growth factor mutations (EGFR) mutation in PSC is similar to that of lung adenocarcinoma with a range of 0%-28% [12] [13] [14] [15] [16] . The efficacy of EGFR tyrosine kinase inhibitors in PSC has varied between studies, and the results have been indeterminate [15, 17] . Even less data is available regarding the ALK translocations. Studies have reported 3-5% of NSCLC demonstrate an EML4-ALK fusion gene [18] [19] [20] . In PSC, single cases of the EML4-ALK rearrangements have been reported and the effects of targeted therapies against this mutation have shown to be varied, but mostly ineffective or transient responses [6, [20] [21] [22] [23] .
In our study, two patients demonstrated EML4-ALK translocations. One of the patients received crizotinib and had the longest overall survival compared to the other patients studied. In addition to EGFR mutations and ALK translocations, MET amplification and MET exon 14 skipping were recently described in PSC, providing another possibility for targeted therapy [12] . Considering that crizotinib targets both ALK and MET mutations, this agent may play an important role in treating patients with PSC [24] . Additional studies are required to determine the efficacy of molecular targeted therapies against PSC.
In addition to chemotherapy and targeted therapy, immunotherapy has demonstrated encouraging results in the treatment of NSCLC. Specifically, monoclonal antibodies directed against the programmed death 1 (PD-1)/PD ligand-1 (PD-L1) system improved overall survival in NSCLC compared to chemotherapy after disease progression [25] . PD-1 and PD-L1 expression has been examined in PSC. Two studies found a prevalence of PD-L1 expression in 53% and 69.2% of sarcomatoid carcinomas, respectively [26, 27] . In a study evaluating pleomorphic carcinomas, a subtype of PSC, the prevalence was even higher at 90.2% [28] . This suggests PSC expresses greater levels of PD-L1 compared to other NSCLCs and may represent a potential therapeutic target for PSC. www.impactjournals.com/oncotarget CONCLUSIONS Overall, pulmonary sarcomatoid carcinoma is a rare, undifferentiated NSCLC histology that has a poor prognosis. Surgery remains the best option in early stage disease. Patients with PSC do not seem to benefit from systemic chemotherapy except perhaps as adjuvant treatment after surgery. Adjuvant chemotherapy does seem to improve overall survival and should be considered in treatment of PSC. Larger prospective studies are needed to further define the efficacy and role of systemic chemotherapy in patients with PSC. Other therapeutic agents, including targeted therapies and immunotherapy also require additional research.
MATERIALS AND METHODS
This retrospective study included all patients with a pathologically confirmed diagnosis of PSC treated at the University of Cincinnati Medical Center (UCMC) between the years 2000-2014 obtained by a review of a pathology database and the institutional tumor registry for these years. Death was considered as the study endpoint. Kaplan-Meier analysis was used to calculate median overall survival (OS) and 95% confidence intervals (CI). The Cox model was used to test the chemotherapy effect adjusted for age, sex and surgery, and determine hazard ratios (HR). Data was analyzed using SAS ® version 9.4. In studies that measure median overall survival in months, 1 month = 30.4 days.
